Signaling molecules as therapeutic targets in allergic diseases

Journal of Allergy and Clinical Immunology

Volumn 112, Issue 2, 2003, Pages 241-250

  Gorska, Magdalena M ^a   Alam, Rafeul ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE   (United States)

Author keywords

Allergy; Asthma; Signal transduction; Therapy

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATASE; PHOSPHOTRANSFERASE; PROTEIN BCL 6; PROTEIN TYROSINE KINASE; RAS PROTEIN; STAT PROTEIN; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR REL;

ALLERGIC DISEASE; CELL FUNCTION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

EID: 0043031428     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2003.1667     Document Type: Article

References (96)

1. Nel AE, Slaughter N. T-cell activation through the antigen receptor. Part 2: Role of signaling cascades in T-cell differentiation, anergy, immune senescence, and development of immunotherapy. J Allergy Clin Immunol 2002;109:901-15.
2. Nel AE. T-cell activation through the antigen receptor. Part 1: Signaling components, signaling pathways, and signal integration at the T-cell antigen receptor synapse. J Allergy Clin Immunol 2002;109:758-70.
3. MacGlashan D Jr. Signal transduction: mechanisms in basophils. J Allergy Clin Immunol 1994;94:1146-51.
4. Ott VL, Cambier JC. Activating and inhibitory signaling in mast cells: new opportunities for therapeutic intervention? J Allergy Clin Immunol 2000;106:429-40.
5. Scharenberg AM, Kinet J-P. Initial events in FcεRI signal transduction. J Allergy Clin Immunol 1994;94:1142-6.
6. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature 1997;387:917-21.
7. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, Mitsui K, et al. A new protein containing an SH2 domain that inhibits JAK kinases. Nature 1997;387:921-4.
8. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, Aono A, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature 1997;387:924-9.
9. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002;2:410-6.
10. Flaswinkel H, Barner M, Reth M. The tyrosine activation motif as a target of protein tyrosine kinases and SH2 domains. Semin Immunol 1995;7:21-7.
11. Bolland S, Ravetch JV. Inhibitory pathways triggered by ITIM-containing receptors. Adv Immunol 1999;72:149-77.
12. Bruhns P, Vely F, Malbec O, Fridman WH, Vivier E, Daeron M. Molecular basis of the recruitment of the SH2 domain-containing inositol 5-phosphatases SHIP1 and SHIP2 by fcgamma RIIB. J Biol Chem 2000;275:37357-64.
13. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6.
14. Weiss A. T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases. Cell 1993;73:209-12.
15. Adachi T, Stafford S, Kayaba H, Chihara J, Alam R. Myosin light chain kinase mediates eosinophil chemotaxis in a mitogen-activated protein kinase-dependent manner. J Allergy Clin Immunol 2003;111:113-6.
16. Pierce KL, Premont RT, Lefkowitz RJ. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 2002;3:639-50.
17. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 2002;285:1-24.
18. O'Shea JJ, Gadina M, Schreiber RD. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell 2002;109(suppl):S121-31.
19. Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol 2001;13:299-306.
20. Takeuchi O, Akira S. MyD88 as a bottle neck in Toll/IL-1 signaling. Curr Top Microbiol Immunol 2002;270:155-67.
21. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 2002;20:55-72.
22. Ray A, Cohn L. Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation. J Clin Invest 1999;104:985-93.
23. Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol 2002;20:761-94.
24. Jordan MS, Singer AL, Koretzky GA. Adaptors as central mediators of signal transduction in immune cells. Nat Immun 2003;4:110-6.
25. Yablonski D, Weiss A. Mechanisms of signaling by the hematopoietic-specific adaptor proteins, SLP-76 and LAT and their B cell counterpart, BLNK/SLP-65. Adv Immunol 2001;79:93-128.
26. Saijo K, Schmedt C, Su IH, Karasuyama H, Lowell CA, Reth M, et al. Essential role of Src-family protein tyrosine kinases in NF-kappaB activation during B cell development. Nat Immun 2003;4:274-9.
27. Goldman FD, Ballas ZK, Schutte BC, Kemp J, Hollenback C, Noraz N, et al. Defective expression of p561ck in an infant with severe combined immunodeficiency. J Clin Invest 1998;102:421-9.
28. Molina TJ, Kishihara K, Siderovski DP, van Ewijk W, Narendran A, Timms E, et al. Profound block in thymocyte development in mice lacking p561ck. Nature 1992;357:161-4.
29. Zhang W, Sommers CL, Burshtyn DN, Stebbins CC, DeJarnette JB, Trible RP, et al. Essential role of LAT in T cell development. Immunity 1999;10:323-32.
30. Clements JL, Yang B, Ross-Barta SE, Eliason SL, Hrstka RF, Williamson RA, et al. Requirement for the leukocyte-specific adapter protein SLP-76 for normal T cell development. Science 1998;281:416-9.
31. Texido G, Su IH, Mecklenbrauker I, Saijo K, Malek SN, Desiderio S, et al. The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation. Mol Cell Biol 2000;20:1227-33.
32. Ueda E, Ohno S, Kuroki T, Livneh E, Yamada K, Yamanishi K, et al. The eta isoform of protein kinase C mediates transcriptional activation of the human transglutaminase 1 gene. J Biol Chem 1996;271:9790-4.
33. Silverman ES, Baron RM, Palmer LJ, Le L, Hallock A, Subramaniam V, et al. Constitutive and cytokine-induced expression of the ETS transcription factor ESE-3 in the lung. Am J Respir Cell Mol Biol 2002;27:697-704.
34. Bukrinsky MI. Cyclophilins: unexpected messengers in intercellular communications. Trends Immunol 2002;23:323-5.
35. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem 2000;7:731-48.
36. Grootendorst DC, Rabe KF. Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 2002;2:61-7.
37. Lewis RS. Calcium signaling mechanisms in T lymphocytes. Annu Rev Immunol 2001;19:497-521.
38. Stenton GR, Ulanova M, Dery RE, Merani S, Kim MK, Gilchrist M, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002;169:1028-36.
39. Kumano K, Nakao A, Nakajima H, Miike S, Kurasawa K, Saito Y, et al. Blockade of JAK2 by tyrphostin AG-490 inhibits antigen-induced eosinophil recruitment into the mouse airways. Biochem Biophys Res Commun 2000;270:209-14.
40. Underwood DC, Osborn RR, Kotzer CJ, Adams JL, Lee JC, Webb EF, et al. SB 239063, a potent p38 MAP kinase inhibitor, reduces inflammatory cytokine production, airways eosinophil infiltration, and persistence. J Pharmacol Exp Ther 2000;293:281-8.
41. Egan PJ, Lawlor KE, Alexander WS, Wicks Ip. Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 2003;111:915-24.
42. Yasukawa H, Yajima T, Duplain H, Iwatate M, Kido M, Hoshijima M, et al. The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J Clin Invest 2003;111:469-78.
43. Kamata T, Yamashita M, Kimura M, Murata K, Inami M, Shimizu C, et al. src homology 2 domain-containing tyrosine phosphatase SHP-1 controls the development of allergic airway inflammation. J Clin Invest 2003;111:109-19.
44. Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002;295:336-8.
45. Lewandoski M. Conditional control of gene expression in the mouse. Nat Rev Genet 2001;2:743-55.
46. Walder RY, Walder JA. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci U S A 1988;85:5011-5.
47. Agrawal S, Jiang Z, Zhao Q, Shaw D, Cai Q, Roskey A, et al. Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: in vitro and in vivo studies. Proc Natl Acad Sci U S A 1997;94:2620-5.
48. Finotto S, De Sanctis GT, Lehr HA, Herz U, Buerke M, Schipp M, et al. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med 2001;193:1247-60.
49. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001;411:494-8.
50. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002;110:563-74.
51. Liu Y, Bishop A, Witucki L, Kraybill B, Shimizu E, Tsien J, et al. Structural basis for selective inhibition of Src family kinases by PP1. Chem Biol 1999;6:671-8.
52. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 1998;273:18623-32.
53. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739.
54. Habisch HJ, Gorren AC, Liang H, Venema RC, Parkinson JF, Schmidt K, et al. Pharmacological interference with dimerization of human neuronal nitric-oxide synthase expressed in adenovirus-infected DLD-1 cells. Mol Pharmacol 2003;63:682-9.
55. Moffett S, Brown DA, Linder ME. Lipid-dependent targeting of G proteins into rafts. J Biol Chem 2000;275:2191-8.
56. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003;17:905-7.
57. Webb Y, Hermida-Matsumoto L, Resh MD. Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids. J Biol Chem 2000;275:261-70.
58. Brassard DL, English JM, Malkowski M, Kirschmeier P, Nagabhushan TL, Bishop WR. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras. Exp Cell Res 2002;273:138-46.
59. Lobell RB, Liu D, Buser CA, Davide JP, DePuy E, Hamilton K, et al. Preclinical and clinical pharmacodynamic assessment of L-778, 123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther 2002;1:747-58.
60. Alcock RA, Dey S, Chendil D, Inayat MS, Mohiuddin M, Hartman G, et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene 2002;21:7883-90.
61. Bordier BB, Marion PL, Ohashi K, Kay MA, Greenberg HB, Casey JL, et al. A prenylation inhibitor prevents production of infectious hepatitis delta virus particles. J Virol 2002;76:10465-72.
62. Amin R, Chen HQ, Tannous M, Gibbs R, Kowluru A. Inhibition of glucose- and calcium-induced insulin secretion from betaTC3 cells by novel inhibitors of protein isoprenylation. J Pharmacol Exp Ther 2002; 303:82-8.
63. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-74.
64. D'Oro U, Vacchio MS, Weissman AM, Ashwell JD. Activation of the Lck tyrosine kinase targets cell surface T cell antigen receptors for lysosomal degradation. Immunity 1997;7:619-28.
65. Loewe R, Holnthoner W, Groger M, Pillinger M, Gruber F, Mechtcheriakova D, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002;168:4781-7.
66. Ettenberg SA, Rubinstein YR, Banerjee P, Nau MM, Keane MM, Lipkowitz S. cbl-b inhibits EGF-receptor-induced apoptosis by enhancing ubiquitination and degradation of activated receptors. Mol Cell Biol Res Commun 1999;2:111-8.
67. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
68. Rao N, Miyake S, Reddi AL, Douillard P, Ghosh AK, Dodge IL, et al. Negative regulation of Lck by Cbl ubiquitin tigase. Proc Natl Acad Sci U S A 2002;99:3794-9.
69. Rao N, Dodge I, Band H. The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system. J Leukoc Biol 2002;71:753-63.
70. Swinney DC, Xu YZ, Scarafia LE, Lee I, Mak AY, Gan QF, et al. Small molecule ubiquitination inhibitor blocks NF-kappa B-dependent cytokine expression in cells and rats. J Biol Chem 2002;277:23573-81.
71. Akimoto T, Numata F, Tamura M, Takata Y, Higashida N, Takashi T, et al. Abrogation of bronchial eosinophilic inflammation and airway hyperreactivity in signal transducers and activators of transcription (STAT)6-deficient mice. J Exp Med 1998;187:1537-42.
72. Donovan CE, Mark DA, He HZ, Liou HC, Kobzik L, Wang Y, et al. NF-kappa B/Rel transcription factors: c-Rel promotes airway hyperresponsiveness and allergic pulmonary inflammation. J Immunol 1999;163:6827-33.
73. Das J, Chen CH, Yang L, Cohn L, Ray P, Ray A. A critical role for NF-kappa B in GATA3 expression and TH2 differentiation in allergic airway inflammation. Nat Immun 2001;2:45-50.
74. Hilliard BA, Mason N, Xu L, Sun J, Lamhamedi-Cherradi SE, Liou HC, et al. Critical roles of c-Rel in autoimmune inflammation and helper T cell differentiation. J Clin Invest 2002;110:843-50.
75. Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, et al. Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 2001;108:739-47.
76. Pandolfi PP, Roth ME, Karis A, Leonard MW, Dzierzak E, Grosveld FG, et al. Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nat Genet 1995;11:40-4.
77. Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000;103:239-52.
78. Hartenstein B, Teurich S, Hess J, Schenkel J, Schorpp-Kistner M, Angel P. Th2 cell-specific cytokine expression and allergen-induced airway inflammation depend on JunB. EMBO J 2002;21:6321-9.
79. Zhang DH, Yang L, Cohn L, Parkyn L, Homer R, Ray P, et al. Inhibition of allergic inflammation in a murine model of asthma by expression of a dominant-negative mutant of GATA-3. Immunity 1999;11:473-82.
80. Murphy KM, Reiner SL. The lineage decisions of helper T cells. Nat Rev Immunol 2002;2:933-44.
81. Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, et al. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity 1999;11:399-409.
82. Kaplan MH, Sun YL, Hoey T, Grusby MJ. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 1996;382:174-7.
83. Ye BH, Cattoretti G, Shen Q, Zhang J, Hawe N, de Waard R, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet 1997;16:161-70.
84. Seto Y, Nakajima H, Suto A, Shimoda K, Saito Y, Nakayama KI, et al. Enhanced Th2 cell-mediated allergic inflammation in Tyk2-deficient mice. J Immunol 2003;170:1077-83.
85. Baron BW, Anastasi J, Thirman MJ, Furukawa Y, Fears S, Kim DC, et al. The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci U S A 2002;99:2860-5.
86. Kim JI, Ho IC, Grusby MJ, Glimcher LH. The transcription factor c-Maf controls the production of interleukin-4 but not other Th2 cytokines. Immunity 1999;10:745-51.
87. Stafford S, Lowell C, Sur S, Alam R. Lyn tyrosine kinase is important for IL-5-stimulated eosinophil differentiation. J Immunol 2002;168:1978-83.
88. Adachi T, Stafford S, Sur S, Alam R. A novel Lyn-binding peptide inhibitor blocks eosinophil differentiation, survival, and airway eosinophilic inflammation. J Immunol 1999;163:939-46.
89. Hibbs ML, Tarlinton DM, Armes J, Grail D, Hodgson G, Maglitto R, et al. Multiple defects in the immune system of Lyn-deficient mice, culminating in autoimmune disease. Cell 1995;83:301-11.
90. Vicentini L, Mazzi P, Caveggion E, Continolo S, Fumagalli L, Lapinet-Vera JA, et al. Fgr deficiency results in defective eosinophil recruitment to the lung during allergic airway inflammation. J Immunol 2002;168:6446-54.
91. Gu H, Said K, Klaman LD, Shen J, Fleming T, Wang Y, et al. Essential role for Gab2 in the allergic response. Nature 2001;412:186-90.
92. Pendl GG, Prieschl EE, Thumb W, Harrer NE, Auer M, Baumruker T. Effects of phosphatidylinositol-3-kinase inhibitors on degranulation and gene induction in allergically triggered mouse mast cells. Int Arch Allergy Immunol 1997;112:392-9.
93. Lu B, Yu H, Chow C, Li B, Zheng W, Davis RJ, et al. GADD45gamma mediates the activation of the p38 and JNK MAP kinase pathways and cytokine production in effector TH1 cells. Immunity 2001;14:583-90.
94. Sugai M, Gonda H, Kusunoki T, Katakai T, Yokota Y, Shimizu A. Essential role of Id2 in negative regulation of IgE class switching. Nat Immunol 2003;4:25-30.
95. Morrow MA, Mayer EW, Perez CA, Adlam M, Siu G. Overexpression of the Helix-Loop-Helix protein Id2 blocks T cell development at multiple stages. Mol Immunol 1999;36:491-503.
96. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2001;2:947-50.